Nomos and Pharma Value have developed a background paper to analyse the AIFA reform defined in recent weeks in the Senate and understand its next steps.
The aim is to offer a tool for the affected interest groups, from patient associations to pharmaceutical companies, via the regions and AIFA staff themselves, to orient themselves on the timing of their ongoing activities.
Nomos and Pharma Value undertake to update the document with legal/institutional news, information and reflections on the basis of forthcoming developments.
Soon, we will also translate it into English.